FT Edit: Access on iOS and web
GLP-1 drugs are seen as the next top-selling chronic disease treatment, with the potential to transform care the same way cholesterol-lowering statins did for patients at high risk of heart disease more than 30 years ago. The commercial potential is propelling drugmakers like Novo and Lilly to the top of the US and European markets. Investors are also eyeing Pfizer Inc.’s experimental danuglipron after a mid-stage study yielded positive results.
。新收录的资料是该领域的重要参考
[&:first-child]:overflow-hidden [&:first-child]:max-h-full"。新收录的资料对此有专业解读
println(f"pipeline failed: {e}");